Package Insert: Information for the Patient
Lacosamide Cinfa 50 mg Film-Coated Tablets
Lacosamide Cinfa 100 mg Film-Coated Tablets
Lacosamide Cinfa 150 mg Film-Coated Tablets
Lacosamide Cinfa 200 mg Film-Coated Tablets
Read this package insert carefully before starting to take this medicine, as it contains important information for you.
This medicine contains lacosamida, which belongs to a group of medicines called “antiepileptic medicines”. These medicines are used to treat epilepsy.
What is lacosamida cinfa used for
Do not takelacosamidaif any of the above applies to you. If you are unsure, consult your doctor or pharmacist before taking this medication.
Consult your doctor before starting to uselacosamidaif:
If any of the above applies to you (or you are unsure), consult your doctor or pharmacist before takinglacosamida.
If you are takinglacosamida, consult your doctor if you experience a new type of seizure or worsening of existing seizures.
If you are takinglacosamidaand experience symptoms of abnormal heart rhythm (such as slow, fast, or irregular heartbeat, palpitations, shortness of breath, dizziness, fainting), consult your doctor immediately (see section 4).
Lacosamidais not recommended for children under 2 years with epilepsy characterized by the onset of partial seizures or for children under 4 years with generalized tonic-clonic seizures. This is because it is not yet known if it is effective and safe for children of this age group.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Particularly, inform your doctor or pharmacist if you are taking any of the following medications that affect the heart, aslacosamidamay also affect the heart:
Also inform your doctor or pharmacist if you are taking any of the following medications, as they may increase or decrease the effect oflacosamidain your body:
If any of the above applies to you (or you are unsure), speak with your doctor or pharmacist before takinglacosamida.
Use ofLacosamida Cinfawith alcohol
As a precaution, do not takelacosamidawith alcohol.
Women of childbearing age should discuss the use of contraceptives with their doctor.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Lacosamidais not recommended if you are pregnant, as its effects on pregnancy and the fetus are unknown.
It is not recommended to breastfeed while takinglacosamida, aslacosamidapasses into breast milk.
Seek advice immediately from your doctor if you are pregnant or plan to become pregnant. They will help you decide if you should takelacosamidaor not.
Do not stop treatment without first speaking with your doctor, as this may increase seizures (crises). A worsening of your condition may also harm the fetus.
You should not drive, cycle, or use any tools or machines until you know if this medication affects you. The reason is thatlacosamidamay cause dizziness or blurred vision.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Other presentations of this medication may be more suitable for children; consult your doctor or pharmacist.
Normally, you will start taking a low dose each day and your doctor will gradually increase the dose over several weeks. When you reach the dose that works well for you, called the “maintenance dose”, you will take the same amount each day.Lacosamidais used as long-term treatment. You will need to continue takinglacosamidauntil your doctor tells you to stop.
The following are the usual recommended doses oflacosamidafor different age groups and weights. Your doctor may prescribe a different dose if you have kidney or liver problems.
Adolescents and children weighing 50 kg or more and adultsWhen takinglacosamidaalone:
The usual starting dose is 50 mg twice a day.
Your doctor may also prescribe a starting dose of 100 mg oflacosamidatwice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 300 mg twice a day.
When takinglacosamidawith other antiepileptic medications:The usual starting dose is 50 mg twice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 200 mg twice a day.
If you weigh 50 kg or more, your doctor may start treatment with a single “loading dose” of 200 mg. Then you will start taking the continuous maintenance dose 12 hours later.
lacosamidais not recommended for children under 4 years.
The dose depends on body weight. Treatment usually starts with the syrup and only changes to tablets if the patient is able to take them and get the correct dose with tablets of different concentrations. Your doctor will prescribe the pharmaceutical form that best suits you.
If you have taken morelacosamidathan you should, consult your doctor immediately. Do not try to drive. You may experience:
In case of overdose or accidental ingestion, consult your doctor or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
The side effects in the nervous system, such as dizziness, may be more pronounced after a single "loading" dose.
Inform your doctor or pharmacist if you experience any of the following side effects:
Very common: may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Frequency not known:cannot be estimated from available data
Other side effects in children
The additional side effects observed in children were fever (pyrexia), nasal congestion (nasopharyngitis), sore throat (pharyngitis), eating less than usual (decreased appetite), changes in behavior, not acting as they normally do (abnormal behavior), and lack of energy (lethargy). Drowsiness (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister pack after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Medications should not be thrown down the drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of lacosamida cinfa
Each lacosamida cinfa 50 mg tablet contains 50 mg of lacosamida.
Each lacosamida cinfa 100 mg tablet contains 100 mg of lacosamida.
Each lacosamida cinfa 150 mg tablet contains 150 mg of lacosamida.
Each lacosamida cinfa 200 mg tablet contains 200 mg of lacosamida.
Core of the tablet: microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl cellulose with low degree of substitution, anhydrous colloidal silica, microcrystalline cellulose silicified (formed by microcrystalline cellulose and anhydrous colloidal silica), crospovidone and magnesium stearate.
Coating: polyvinyl alcohol, macrogol, talc, titanium dioxide (E-171) and colorants*
*The colorants are:
50 mg tablets: iron oxide red (E-172).
100 mg tablets: iron oxide yellow (E-172).
150 mg tablets: iron oxide red (E-172), iron oxide yellow (E-172).
200 mg tablets: carmine of indigo (E-132).
Appearance of the product and contents of the package
Lacosamida cinfa is available in packages with 14, 28 and 56 film-coated tablets in PVC/PVDC-Aluminum blister packaging.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Laboratorios Cinfa, S.A
Carretera Olaz-Chipi, 10. Industrial Estate Areta
31620 Huarte (Navarra) – Spain
Last review date of this leaflet:May 2025
For detailed information about this medicine, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Lacosamida cinfa 50 mg film-coated tablets
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:
https://cima.aemps.es/cima/dochtml/p/86515/P_86515.html
QR code to:https://cima.aemps.es/cima/dochtml/p/86515/P_86515.html
Lacosamida cinfa 100 mg film-coated tablets
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:
https://cima.aemps.es/cima/dochtml/p/86512/P_86512.html
QR code to:https://cima.aemps.es/cima/dochtml/p/86512/P_86512.html
Lacosamida cinfa 150 mg film-coated tablets
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:
https://cima.aemps.es/cima/dochtml/p/86513/P_86513.html
QR code to:https://cima.aemps.es/cima/dochtml/p/86513/P_86513.html
Lacosamida cinfa 200 mg film-coated tablets
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your smartphone. You can also access this information at the following internet address:https://cima.aemps.es/cima/dochtml/p/86514/P_86514.html
QR code to:https://cima.aemps.es/cima/dochtml/p/86514/P_86514.html
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.